₹512.95
−4.89%NSE close, 16 Nov 2026
−14.24%
Blue Jet Healthcare is a small cap company in the Healthcare sector, listed on NSE under the symbol BLUEJET. At ₹512.95 a share, the market values the whole company at ₹9,709 crore.
In FY26, it reported sales of ₹947 crore and a net profit of ₹248 crore, an operating margin of 31.0%.
The market values the company at 34.0 times its profit over the last twelve months and 4.22 times its book value; its return on equity is 12.4% and it has almost no borrowings.
Promoters hold 73.15% of the shares. Foreign institutions hold 0.82%, and domestic institutions, mutual funds among them, 7.49%.
Over the past year the share price has fallen 8.7%, and it is 20.8% below its 52-week high.
Companies of a similar size in the same sector include Akums Drugs and Pharmaceuticals, Park Medi World, Viyash Scientific and Yatharth Hospital & Trauma Care Services.
₹ crore. Standalone figures: the company files no consolidated results.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
| Akums Drugs and Pharmaceuticals | ₹722.20 | ₹11,367 cr | 31.2 | 10.4% | +31.90% | +56.88% |
| Park Medi World | ₹245.03 | ₹10,584 cr | 41.3 | 11.9% | n/a | n/a |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 |
Disclosure regarding signing of Memorandum of Understanding
Transcript
Link of Recording
Monitoring Agency Report for the quarter ended September 30, 2026
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 | 376 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 | 195 | 257 |
| Operating profit | 54.6 | 53.1 | 44.3 | 69.5 | 124 | 140 | 121 | 55.0 | 46.9 | 71.3 | 98.1 | 119 |
| Operating margin | 32.7% | 28.9% | 27.2% | 33.4% | 39.0% | 41.1% | 34.1% | 33.2% | 24.4% | 30.4% | 33.5% | 31.6% |
| Other income | 6.8 | 8.8 | 8.7 | 12.1 | 13.2 | 12.2 | 8.3 | 24.3 | 13.2 | 22.9 | 15.2 | 26.2 |
| Interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 4.6 | 0.3 | 0.6 | 0.7 | 0.6 |
| Depreciation | 7.9 | 7.7 | 3.5 | 4.6 | 4.8 | 5.0 | 5.7 | 5.9 | 6.0 | 6.5 | 6.7 | 6.9 |
| Profit before tax | 43.7 | 54.2 | 49.5 | 76.9 | 132 | 147 | 123 | 68.7 | 53.8 | 87.2 | 106 | 137 |
| Tax | 11.6 | 14.5 | 11.7 | 18.6 | 33.5 | 37.1 | 31.7 | 16.6 | 13.6 | 22.8 | 27.7 | 34.9 |
| Net profit | 32.1 | 39.5 | 37.8 | 58.4 | 99.0 | 110 | 91.2 | 52.1 | 40.2 | 64.3 | 78.3 | 103 |
| EPS (₹) | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 | 5.46 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 45.8 | 334 | −25.6 |
| From investing | −35.2 | −276 | −711 |
| From financing | −18.6 | −30.7 | 753 |
| Spent on fixed assets | −79.9 | 0 | −76.1 |
| Free cash flow | −34.1 | 334 | −102 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 29.6% | 26.2% |
| Operating margin | 36.7% | 31.0% |
| Return on equity | 26.9% | 18.2% |
| Return on capital employed | 35.8% | 24.9% |
| Return on assets | 21.5% | 15.1% |
| Debt to equity | 0.00 | 0.00 |
| Interest coverage | 4,062.00 | 54.30 |
| Debt to assets | 0.00 | 0.00 |
| Current ratio | 3.93 | 4.21 |
| Quick ratio | 2.90 | 3.38 |
| Cash ratio | 0.13 | 0.27 |
| Asset turnover | 0.73 | 0.58 |
| Fixed asset turnover | 3.97 | 3.01 |
| Inventory turnover | 1.70 | 2.30 |
| Receivables turnover | 2.90 | 2.80 |
| Gross margin | 55.2% | 54.0% |
| Cash from operations to profit | 15.0% | 135.0% |
| Effective tax rate | 24.8% | 25.5% |
| 10.0% |
| +54.40% |
| +34.65% |
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
|---|
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
|---|
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
|---|
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
|---|
Presentation
The financial results for the period ended September 30, 2026.
Schedule of meet
A copy Srutinizers report of Annual General Meeting held on September 21, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 21, 2026
Business Responsibility and Sustainability Report for the FY 2025-26
Notice of Annual General Meeting to be held on September 21, 2026
Record date for the purpose of Dividend is 14-Sep-2026.
Outcome of Board Meeting held on August 03, 2026.
Outcome of Board Meeting held on August 03, 2026.
The financial results for the period ended Jun 30, 2026.